Through
5/7
A round-up of Penn mentions in local, national, and international media.
Penn In the News
Daniel Hopkins of the School of Arts & Sciences says that our current highly nationalized political system drives voters to focus on symbolic, emotionally fraught, easily accessible issues that resonate throughout the country.
Penn In the News
John Wherry of the Perelman School of Medicine says that bivalent vaccines are not providing perfect protection from omicron variants.
Penn In the News
On an episode of “All Things Considered,” Paul Offit of the Perelman School of Medicine says that there’s no evidence yet that the bivalent vaccine is any better than the original COVID vaccines.
Penn In the News
On a segment of “Consider This,” Maurice Schweitzer of the Wharton School explains how our culture encourages cheating and whether that affects his thoughts on human nature.
Penn In the News
Paul Offit of the Perelman School of Medicine says that uncertain benefits for children and lack of historical data on bivalent vaccines might not justify pediatric authorizations for omicron boosters.
Penn In the News
Holly Fernandez Lynch of the Perelman School of Medicine says that the FDA’s current trajectory has been characterized by increased willingness to accept weaker evidence.
Penn In the News
Mitesh Patel of the Perelman School of Medicine discusses how to apply gamification techniques to everyday fitness routines for motivation and enjoyment.
Penn In the News
Daniel Garrett of the Wharton School says that Texas’s top five lenders left the municipal bond market because they refused to support the manufacture of AR-15-style weapons, estimating that their departure has cost Texan taxpayers an extra 300- to $500 million in interest.
Penn In the News
Shelley Welton of Penn Carey Law and the Kleinman Center for Energy Policy says that blaming renewables is a distraction, a way to forestall a transition that is underway but needs to be moving faster.
Penn In the News
Paul Offit of the Perelman School of Medicine says that the FDA needs solid data to ensure that the new BA.4/5 boosters have a dramatically greater neutralizing antibody response.